Collegium Boosts ADHD Portfolio with AZSTARYS Acquisition, Reports Mixed Q2 Results — Collegium Pharmaceutical, Inc.

Event summary

Collegium completed the acquisition of AZSTARYS from Corium Therapeutics in May, adding a complementary ADHD medication with patent protection through 2037.
JORNAY PM net revenue grew 41% year-over-year to $46.1 million, driven by record-high prescriber adoption.
Total Q2 net revenues increased 6% year-over-year to $199.9 million, but GAAP net loss was ($15.1) million due to higher operating expenses.
Collegium lowered full-year revenue guidance to $825–$855 million from $865–$895 million, citing lower-than-expected Nucynta franchise revenues.

The big picture

Collegium's acquisition of AZSTARYS strengthens its ADHD portfolio, but mixed Q2 results highlight challenges in its pain management segment. The company faces pressure to sustain growth amid declining Nucynta revenues while managing higher operating expenses post-acquisition. Its ability to integrate and commercialize AZSTARYS effectively will be critical for long-term value creation.

What we're watching

Integration Success: Whether Collegium can fully integrate AZSTARYS and leverage its expanded salesforce to drive ADHD portfolio growth.
Pain Portfolio Pressures: The pace at which Nucynta franchise revenues decline will impact overall financial stability.
Market Positioning: How Collegium differentiates itself in the competitive ADHD market with JORNAY PM and AZSTARYS.